Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations

NCT04161391 is registered in ClinicalTrials.gov with Turning Point Therapeutics, Inc. as lead sponsor.

NCT NCT04161391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04161391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Lead sponsor
Turning Point Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
December 6, 2019
Completion date
May 22, 2023
Enrollment
41 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, medullary thyroid cancer, metastatic solid tumor, non small cell lung cancer, ret gene mutation